Abstract
BackgroundCarfilzomib (Kyprolis®) is a second-generation, selective and irreversible proteasome inhibitor. Profound knowledge about the physicochemical stability is necessary in order to determine the ‘beyond-use-dates’ of the reconstituted and diluted ready-to-administer...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
